PROSPER: trial design

Slides:

Advertisements

Similar presentations

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels Frank M. Sacks, M.D., Marc A. Pfeffer,

Advertisements

Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol VA-HIT Rubins, HB, et.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Cholesterol and Lipids TIPS Wokefield Park 15/5/2013.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Cholesterol quintile (mg/dL)

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:

Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

Bezafibrate Infarction Prevention Trial (BIP) Results Presented at the European Society of Cardiology Meeting Vienna, Austria 1998.

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.

ASCOT and Steno-2: Aggressive risk reduction benefits two different patient populations *Composite of CV death, nonfatal MI or stroke, revascularization,

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

4S: Scandinavian Simvastatin Survival Study

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Baseline characteristics of HPS participants by prior cerebrovascular disease.

FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Pravastatin in Elderly Individuals at Risk of Vascular Disease

The American Heart Association Presented by Dr. Steven E. Nissen

ELIGIBILITY: MRC/BHF Heart Protection Study

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

AIM HIGH Niacin plus Statin to prevent vascular events

HDL cholesterol and cardiovascular risk Epidemiological evidence

First time a CETP inhibitor shows reduction of serious CV events

Scandinavian Simvastatin Survival Study (4S)

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

TNT: Baseline and final LDL cholesterol levels

The Hypertension in the Very Elderly Trial (HYVET)

The results of the SHARP trial

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Description of studies for pooled analyses

Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.

LRC-CPPT and MRFIT Content Points:

Potential mechanisms whereby statins may reduce the risk of stroke

Baseline Characteristics According to Sex

Cause of death Treatment-arm events, % (n=45 054)

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Baseline Characteristics of the Subjects*

Characteristics of included studies

The results of the SHARP trial

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Comparison of Baseline Characteristics by Primary End Point

FIELD: Primary outcome

Presentation transcript:

PROSPER: trial design Shepherd J et al. Lancet. 2002;360:1623-30

PROSPER: Baseline Clinical Characteristics Placebo Pravastatin Age (yrs) 75.3 75.4 Female (%) 52 History of any vascular disease, n (%) 1259 (43.2) 1306 (45.2) Current smoker, n (%) 805 (27.6) 753 (26.0) History of hypertension, n (%) 1793 (61.6) 1799 (62.2) Mean SBP/DBP (mm Hg) 154.6/83.94 154.7/83.64 History of diabetes, n (%) 320 (11.0) 303 (10.5) Shepherd J et al. Lancet. 2002;360:1623-30

PROSPER: Baseline Lipid Profile Placebo Pravastatin Total cholesterol (mg/dL) 221 HDL-C (mg/dL) 50 LDL-C (mg/dL) 147 Triglycerides (mg/dL) 133 Shepherd J et al. Lancet. 2002;360:1623-30

PROSPER: primary endpoint (coronary death, nonfatal MI, and stroke). Shepherd J et al. Lancet. 2002;360:1623-30

PROSPER: rates of CHD-related death and nonfatal MI Shepherd J et al. Lancet. 2002;360:1623-30

PROSPER: rate of CHD-related death Shepherd J et al. Lancet. 2002;360:1623-30

PROSPER: rates of fatal and nonfatal stroke Shepherd J et al. Lancet. 2002;360:1623-30